Agilent has acquired a 48% stake in genome sequencing company Lasergen and secured a two-year option to buy the remaining shares for another $105m.
US-based biotechnology company Lasergen received $80m in funding on Monday from research and manufacturing company Agilent Technologies in return for a 48% stake.
Agilent has also secured an option to purchase the remaining shares in Lasergen for an additional $105m until March 2, 2018.
Founded in 2002, Lasergen is working on a next-generation sequencing platform named Lightning Terminators that it hopes will provide faster, more accurate and cheaper genome sequencing.
Lasergen and Agilent will work together to develop a workflow…
